Oct 29, 2025 · These highlights do not include all the information needed to use LIBTAYO safely and effectively. See full prescribing information for LIBTAYO. LIBTAYO® (cemiplimab-rwlc) injection, for .
Advise the patient to read the FDA-approved patient labeling (Medication Guide). Immune-Mediated Adverse Reactions Advise patients that LIBTAYO can cause immune-mediated adverse reactions.
Aug 16, 2025 · FAQ What type of drug is Cemiplimab? Cemiplimab is a fully human monoclonal antibody and an immune checkpoint inhibitor. It blocks the PD-1 receptor on T cells, helping the.
The recommended cemiplimab-rwlc dose and schedule is 350 mg as an intravenous infusion over 30 minutes every 3 weeks. View full prescribing information for LIBTAYO.
